A citation-based method for searching scientific literature

Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Vincent Chia, Sabine Glaser, Philippe Pultar, Sylvia Zhao, Bin Peng, Mikhail Akimov, Daniel S W Tan. J Clin Oncol 2018
Times Cited: 129



Helena A Yu, Maria E Arcila, Natasha Rekhtman, Camelia S Sima, Maureen F Zakowski, William Pao, Mark G Kris, Vincent A Miller, Marc Ladanyi, Gregory J Riely. Clin Cancer Res 2013
Times Cited: 1492




List of shared articles



Times cited

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Jin-Ji Yang, Jian Fang, Yong-Qian Shu, Jian-Hua Chang, Gong-Yan Chen, Jian Xing He, Wei Li, Xiao-Qing Liu, Nong Yang, Caicun Zhou,[...]. Invest New Drugs 2021
1

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Ezra Y Rosen, Melissa L Johnson, Sarah E Clifford, Romel Somwar, Jennifer F Kherani, Jieun Son, Arrien A Bertram, Monika A Davare, Eric Gladstone, Elena V Ivanova,[...]. Clin Cancer Res 2021
23

Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective.
Julia Lai-Kwon, Crescens Tiu, Abhijit Pal, Sachin Khurana, Anna Minchom. Crit Rev Oncol Hematol 2021
4

Crizotinib in Patients With MET-Amplified NSCLC.
D Ross Camidge, Gregory A Otterson, Jeffrey W Clark, Sai-Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I Shapiro, Mark A Socinski, Danielle A Murphy, Umberto Conte,[...]. J Thorac Oncol 2021
6

Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.
Keunchil Park, Gee-Chen Chang, Giuseppe Curigliano, Wan-Teck Lim, Ross A Soo, Miguel A Molina-Vila, Valérie Cattan, Hélène Darville, Eric Gandossi, Veronika Smutna,[...]. Lung Cancer 2021
2

GABRP sustains the stemness of triple-negative breast cancer cells through EGFR signaling.
Xiyin Li, Hairui Wang, Xing Yang, Xiaoqi Wang, Lina Zhao, Li Zou, Qin Yang, Zongliu Hou, Jing Tan, Honglei Zhang,[...]. Cancer Lett 2021
0

When the MET receptor kicks in to resist targeted therapies.
Marie Fernandes, Philippe Jamme, Alexis B Cortot, Zoulika Kherrouche, David Tulasne. Oncogene 2021
0


Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.
Emma-Anne Karlsen, Sam Kahler, Joan Tefay, Shannon R Joseph, Fiona Simpson. Cells 2021
2


Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer.
Yiming Zhao, Shuyuan Wang, Zhengyu Yang, Yu Dong, Yanan Wang, Lele Zhang, Hai Hu, Baohui Han. Front Oncol 2021
0


Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer.
Pınar Özden Eser, Raymond M Paranal, Jieun Son, Elena Ivanova, Yanan Kuang, Heidi M Haikala, Ciric To, Jeffrey J Okoro, Kshiti H Dholakia, Jihyun Choi,[...]. Sci Transl Med 2021
0

Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.
Damien Reita, Lucile Pabst, Erwan Pencreach, Eric Guérin, Laurent Dano, Valérie Rimelen, Anne-Claire Voegeli, Laurent Vallat, Céline Mascaux, Michèle Beau-Faller. Cancers (Basel) 2021
1

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance.
Li Liu, Jingjing Qu, Jianfu Heng, Chunhua Zhou, Yi Xiong, Haiyan Yang, Wenjuan Jiang, Liang Zeng, Songlin Zhu, Yongchang Zhang,[...]. Front Oncol 2021
1

Modeling restoration of gefitinib efficacy by co-administration of MET inhibitors in an EGFR inhibitor-resistant NSCLC xenograft model: A tumor-in-host DEB-based approach.
Elena M Tosca, Glenn Gauderat, Sylvain Fouliard, Mike Burbridge, Marylore Chenel, Paolo Magni. CPT Pharmacometrics Syst Pharmacol 2021
2


First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer.
Xingsheng Hu, Xin Zheng, Sheng Yang, Lin Wang, Xuezhi Hao, Xinge Cui, Lieming Ding, Li Mao, Pei Hu, Yuankai Shi. J Hematol Oncol 2020
1

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Sang-We Kim, James Chih-Hsin Yang, Jong Seok Lee, Wu-Chou Su, Dariusz Kowalski,[...]. Lancet Oncol 2020
106

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, Adam Langenbucher, Jessica J Lin, Marguerite M Rooney, Kylie Prutisto-Chang, Audris Oh, Nathaniel A Adams, Beow Y Yeap,[...]. Clin Cancer Res 2020
45

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
M Schuler, R Berardi, W-T Lim, M de Jonge, T M Bauer, A Azaro, M Gottfried, J-Y Han, D H Lee, M Wollner,[...]. Ann Oncol 2020
30

Comprehensive review of targeted therapy for colorectal cancer.
Yuan-Hong Xie, Ying-Xuan Chen, Jing-Yuan Fang. Signal Transduct Target Ther 2020
149

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Miriam Grazia Ferrara, Vincenzo Di Noia, Ettore D'Argento, Emanuele Vita, Paola Damiano, Antonella Cannella, Marta Ribelli, Sara Pilotto, Michele Milella, Giampaolo Tortora,[...]. Cancers (Basel) 2020
23


Targeting MET Dysregulation in Cancer.
Gonzalo Recondo, Jianwei Che, Pasi A Jänne, Mark M Awad. Cancer Discov 2020
21

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
Yubo Wang, Panwen Tian, Lei Xia, Li Li, Rui Han, Mengxiao Zhu, Analyn Lizaso, Tian Qin, Min Li, Bing Yu,[...]. Lung Cancer 2020
6


Molecular therapeutic targets in non-small cell lung cancer.
Kamya Sankar, Shirish M Gadgeel, Angel Qin. Expert Rev Anticancer Ther 2020
9


Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date.
Olivier Bylicki, Nicolas Paleiron, Jean-Baptiste Assié, Christos Chouaïd. Onco Targets Ther 2020
8

Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Toshio Fujino, Kenichi Suda, Tetsuya Mitsudomi. Expert Opin Emerg Drugs 2020
5

Lung cancer management: monitoring and treating resistance development in third-generation EGFR TKIs.
D Franceschini, S Rossi, M Loi, I Chiola, F Piccoli, F R Lutman, G Finocchiaro, L Toschi, A Santoro, M Scorsetti. Expert Rev Anticancer Ther 2020
0